You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company said it will use the funding in part to accelerate the development of products based on its proprietary de novo nucleic acid synthesis technology.
The BGI Group subsidiary said it plans to strengthen its R&D and instrument production, targeting a global sequencing market it expects to grow to $12.45 billion in 2022.
The La Jolla, California-based firm plans to use the funds to accelerate research partnerships around its LunaDNA genomic data sharing platform.
BrightEdge was founded by the American Cancer Society to invest in for-profit companies developing novel cancer therapeutics and diagnostics.
The Boston-based company offers a DNA test for dogs that it said can provide information on breed, ancestry, health, and disease risk.
Sano will use the funding to support its research platform, through which individuals can submit their medical history and genetic data for research studies.
The company — which is based in the US and trades on the Toronto Stock Exchange — announced plans for the private placement earlier this month.
The company has initial financing of $35 million, and has licensed its foundational SHERLOCK and INSPECTR technologies from the Broad and Harvard, respectively.
The company — a spinout of the New York Genome Center — said it will use the funding in part to develop its technologies for new applications in agriculture.
The company said it intends to use the proceeds of the placement to continue work on its microfluidic PCR-based platform for pathogen detection.
A German shepherd called Nala has had her genome sequenced.
A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?
Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.
In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.